

Global Sun Pharma Advanced Research Company Ltd. Drugs and Companies Pipeline Review H1 2016

*Sun Pharma Advanced Research Company Ltd.
Product Pipeline Review 2016*

PUNE, INDIA, August 30, 2016

/EINPresswire.com/ -- Summary

'[Sun Pharma Advanced Research Company Ltd.](#) - Product Pipeline Review - 2016', provides an overview of the Sun Pharma Advanced Research Company Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sun Pharma Advanced Research Company Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Complete report details @

<https://www.wiseguyreports.com/reports/619234-sun-pharma-advanced-research-company-ltd-product-pipeline-review-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619234-sun-pharma-advanced-research-company-ltd-product-pipeline-review-2016>

Scope



- The report provides a snapshot of the pipeline therapeutic landscape of Sun Pharma Advanced Research Company Ltd.
- The report provides overview of Sun Pharma Advanced Research Company Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Sun Pharma Advanced Research Company Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Sun Pharma Advanced Research Company Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Sun Pharma Advanced Research Company Ltd.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sun Pharma Advanced Research Company Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sun Pharma Advanced Research Company Ltd.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619234-sun-pharma-advanced-research-company-ltd-product-pipeline-review-2016>

Key points in table of content

Table of Contents 2

List of Tables 5

List of Figures 5

Sun Pharma Advanced Research Company Ltd. Snapshot 6

Sun Pharma Advanced Research Company Ltd. Overview 6

Key Information 6

Key Facts 6

Sun Pharma Advanced Research Company Ltd. - Research and Development Overview 7

Key Therapeutic Areas 7

Sun Pharma Advanced Research Company Ltd. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Sun Pharma Advanced Research Company Ltd. - Pipeline Products Glance 15

Sun Pharma Advanced Research Company Ltd. - Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Filing rejected/Withdrawn Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Sun Pharma Advanced Research Company Ltd. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Sun Pharma Advanced Research Company Ltd. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Sun Pharma Advanced Research Company Ltd. - Drug Profiles 22
latanoprost 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
baclofen ER 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
tildrakizumab 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
paclitaxel albumin free 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
tizanidine hydrochloride ER 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SUNK-706 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
(fluticasone propionate + salmeterol xinafoate) 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
docetaxel 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
octreotide acetate SR 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SUN-0597 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
brimonidine tartrate 33
Product Description 33
Mechanism of Action 33

R&D Progress 33
hydrocodone bitartrate 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
minocycline hydrochloride 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
morphine sulfate 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
oxycodone hydrochloride 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Gene Therapy for Ocular Diseases 38
Product Description 38
Mechanism of Action 38
R&D Progress 38

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619234

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2018 IPD Group, Inc. All Right Reserved.